The global Glucagon Like Peptide-1 (GLP-1) Agonists market size was valued at US$ 111250 million in 2024 and is forecast to a readjusted size of USD 490450 million by 2031 with a CAGR of 23.9% during review period.
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
The Glucagon-Like Peptide-1 (GLP-1) Agonists market, which focuses on drugs used for treating type 2 diabetes and obesity, is influenced by several important drivers and challenges:
麻豆原创 Drivers:
Rising Prevalence of Diabetes and Obesity: The increasing global incidence of type 2 diabetes and obesity is driving demand for GLP-1 agonists, as they are effective in controlling blood sugar levels and aiding weight loss.
Shift Towards Injectable and Oral Therapies: Growing patient acceptance of injectable therapies (such as GLP-1 agonists) and the introduction of oral GLP-1 agonists (like semaglutide) are expanding the market.
Favorable Clinical Outcomes: GLP-1 agonists have shown promising results in managing glycemic control, cardiovascular risk reduction, and weight management, making them a preferred option among healthcare providers.
Increased Awareness and Screening: Governments and healthcare organizations are running campaigns to increase awareness about diabetes management, which is boosting demand for GLP-1 agonists.
Product Innovations: Continuous innovations and the development of longer-acting GLP-1 formulations with fewer side effects are improving patient compliance and market growth.
麻豆原创 Challenges:
High Treatment Costs: GLP-1 agonists tend to be expensive, which can limit access, particularly in low-income or underdeveloped healthcare systems.
Side Effects and Contraindications: Some patients experience gastrointestinal side effects (like nausea and vomiting) with GLP-1 agonists, potentially limiting widespread use.
Competition from Other Diabetes Treatments: While GLP-1 agonists are effective, there is stiff competition from other diabetes drugs, including DPP-4 inhibitors, SGLT2 inhibitors, and insulin therapies.
Patient Adherence: Although the drug is effective, some patients may struggle with the required injections (for injectable GLP-1 agonists) or discontinuation due to side effects, leading to adherence challenges.
Regulatory and Reimbursement Barriers: The approval process for new GLP-1 agonist formulations, coupled with inconsistent reimbursement policies, can hinder the availability of these drugs in certain markets.
Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry. United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists The second place is Europe.
This report is a detailed and comprehensive analysis for global Glucagon Like Peptide-1 (GLP-1) Agonists market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Glucagon Like Peptide-1 (GLP-1) Agonists market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Glucagon Like Peptide-1 (GLP-1) Agonists market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Glucagon Like Peptide-1 (GLP-1) Agonists market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Glucagon Like Peptide-1 (GLP-1) Agonists market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Glucagon Like Peptide-1 (GLP-1) Agonists
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Glucagon Like Peptide-1 (GLP-1) Agonists market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, GSK, Hanson, Shanghai Benemae, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Glucagon Like Peptide-1 (GLP-1) Agonists market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Dulaglutide
Exenatide
Liraglutide
Benaglutide
Other
麻豆原创 segment by Application
Diabetes
Obesity
Major players covered
Novo Nordisk
Eli Lilly
AstraZeneca
Sanofi
GSK
Hanson
Shanghai Benemae
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Glucagon Like Peptide-1 (GLP-1) Agonists product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, with price, sales quantity, revenue, and global market share of Glucagon Like Peptide-1 (GLP-1) Agonists from 2020 to 2025.
Chapter 3, the Glucagon Like Peptide-1 (GLP-1) Agonists competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Glucagon Like Peptide-1 (GLP-1) Agonists breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Glucagon Like Peptide-1 (GLP-1) Agonists market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Glucagon Like Peptide-1 (GLP-1) Agonists.
Chapter 14 and 15, to describe Glucagon Like Peptide-1 (GLP-1) Agonists sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Dulaglutide
1.3.3 Exenatide
1.3.4 Liraglutide
1.3.5 Benaglutide
1.3.6 Other
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Diabetes
1.4.3 Obesity
1.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists 麻豆原创 Size & Forecast
1.5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity (2020-2031)
1.5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Novo Nordisk
2.1.1 Novo Nordisk Details
2.1.2 Novo Nordisk Major Business
2.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
2.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Novo Nordisk Recent Developments/Updates
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business
2.2.3 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
2.2.4 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Eli Lilly Recent Developments/Updates
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business
2.3.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
2.3.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 AstraZeneca Recent Developments/Updates
2.4 Sanofi
2.4.1 Sanofi Details
2.4.2 Sanofi Major Business
2.4.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
2.4.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Sanofi Recent Developments/Updates
2.5 GSK
2.5.1 GSK Details
2.5.2 GSK Major Business
2.5.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
2.5.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 GSK Recent Developments/Updates
2.6 Hanson
2.6.1 Hanson Details
2.6.2 Hanson Major Business
2.6.3 Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
2.6.4 Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Hanson Recent Developments/Updates
2.7 Shanghai Benemae
2.7.1 Shanghai Benemae Details
2.7.2 Shanghai Benemae Major Business
2.7.3 Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
2.7.4 Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Shanghai Benemae Recent Developments/Updates
3 Competitive Environment: Glucagon Like Peptide-1 (GLP-1) Agonists by Manufacturer
3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Manufacturer (2020-2025)
3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturer (2020-2025)
3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Glucagon Like Peptide-1 (GLP-1) Agonists by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturer 麻豆原创 Share in 2024
3.5 Glucagon Like Peptide-1 (GLP-1) Agonists 麻豆原创: Overall Company Footprint Analysis
3.5.1 Glucagon Like Peptide-1 (GLP-1) Agonists 麻豆原创: Region Footprint
3.5.2 Glucagon Like Peptide-1 (GLP-1) Agonists 麻豆原创: Company Product Type Footprint
3.5.3 Glucagon Like Peptide-1 (GLP-1) Agonists 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists 麻豆原创 Size by Region
4.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Region (2020-2031)
4.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Region (2020-2031)
4.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Region (2020-2031)
4.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value (2020-2031)
4.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value (2020-2031)
4.4 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value (2020-2031)
4.5 South America Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value (2020-2031)
4.6 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Type (2020-2031)
5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Type (2020-2031)
5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Application (2020-2031)
6.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Application (2020-2031)
6.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Application (2020-2031)
7 North America
7.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Type (2020-2031)
7.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Application (2020-2031)
7.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists 麻豆原创 Size by Country
7.3.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Country (2020-2031)
7.3.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Type (2020-2031)
8.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Application (2020-2031)
8.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists 麻豆原创 Size by Country
8.3.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Country (2020-2031)
8.3.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists 麻豆原创 Size by Region
9.3.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Type (2020-2031)
10.2 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Application (2020-2031)
10.3 South America Glucagon Like Peptide-1 (GLP-1) Agonists 麻豆原创 Size by Country
10.3.1 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Country (2020-2031)
10.3.2 South America Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists 麻豆原创 Size by Country
11.3.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Glucagon Like Peptide-1 (GLP-1) Agonists 麻豆原创 Drivers
12.2 Glucagon Like Peptide-1 (GLP-1) Agonists 麻豆原创 Restraints
12.3 Glucagon Like Peptide-1 (GLP-1) Agonists Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Glucagon Like Peptide-1 (GLP-1) Agonists and Key Manufacturers
13.2 Manufacturing Costs Percentage of Glucagon Like Peptide-1 (GLP-1) Agonists
13.3 Glucagon Like Peptide-1 (GLP-1) Agonists Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Glucagon Like Peptide-1 (GLP-1) Agonists Typical Distributors
14.3 Glucagon Like Peptide-1 (GLP-1) Agonists Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Novo Nordisk
Eli Lilly
AstraZeneca
Sanofi
GSK
Hanson
Shanghai Benemae
听
听
*If Applicable.
